The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 2, 2016, Pages 303-310

  Graffner, H ^a   Gillberg, P G ^a,b   Rikner, L ^a   Marschall, H U ^c  

^a Albireo ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

7 ALPHA HYDROXY 4 CHOLESTEN 3 ONE; A 4250; BILE ACID; CHENODEOXYCHOLIC ACID; CHOLESTEROL DERIVATIVE; CHOLIC ACID; DIGESTIVE TRACT AGENT; FIBROBLAST GROWTH FACTOR 19; ILEAL BILE ACID TRANSPORTER INHIBITOR; PLACEBO; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; 7 ALPHA-HYDROXY-4-CHOLESTEN-3-ONE; BILE ACID BINDING PROTEINS; CARRIER PROTEIN; CHOLEST 4 EN 3 ONE; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; MEMBRANE PROTEIN;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; BILE ACID BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG TOLERABILITY; ENTEROHEPATIC CIRCULATION; FECES LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TERMINAL ILEUM; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECTS; FECES; ILEUM; INTESTINE; METABOLISM; PHASE 1 CLINICAL TRIAL;

ADULT; BILE ACIDS AND SALTS; CARRIER PROTEINS; CHENODEOXYCHOLIC ACID; CHOLESTENONES; DOUBLE-BLIND METHOD; ENTEROHEPATIC CIRCULATION; FECES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; ILEUM; INTESTINES; MALE; MEMBRANE GLYCOPROTEINS;

EID: 84955173864     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13457     Document Type: Article

References (15)

1. Dawson PA, Haywood J, Craddock AL, et al,. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem 2003; 278: 33920-7.
2. Baghdasaryan A, Fuchs C, Österreicher C, et al,. Inhibition of intestinal bile acid absorption protects against cholestatic liver and bile duct injury in a mouse model of cholestatic liver disease. J Hepatol 2015. In press.
3. Hofmann AF, Mangelsdorf DJ, Kliewer SA,. Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release. Clin Gastroenterol Hepatol 2009; 7: 1151-4.
4. Holt JA, Luo G, Billin AN, et al,. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003; 17: 1581-91.
5. Lundasen T, Galman C, Angelin B, Rudling M,. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260: 530-6.
6. Axelson M, Bjorkhem I, Reihner E, Einarsson K,. The plasma level of 7 alpha-hydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7 alpha-hydroxylase in man. FEBS Lett 1991; 284: 216-8.
7. Tagliacozzi D, Mozzi AF, Casetta B, et al,. Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. Clin Chem Lab Med 2003; 41: 1633-41.
8. Camilleri M,. Bile acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liv 2015; 9: 332-9.
9. Simren M, Bajor A, Gillberg PG, Rudling M, Abrahamsson H,. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation-a double-blind study. Aliment Pharmacol Ther 2011; 34: 41-50.
10. Chey WD, Camilleri M, Chang L, Rikner L, Graffner H,. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 2011; 106: 1803-12.
11. Zarrinpar A, Loomba R,. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 36: 909-21.
12. Brufau G, Stellaard F, Prado K, et al,. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 2010; 52: 1455-64.
13. Le TA, Chen J, Changchien C, et al,. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012; 56: 922-32.
14. Mudaliar S, Henry RR, Sanyal AJ, et al,. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-82 e1.
15. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al,. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956-65.